Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1978 2
1983 1
1985 1
1987 1
1988 4
1989 1
1990 3
1991 1
1992 1
1993 3
1994 4
1995 4
1997 2
1998 2
1999 2
2000 2
2001 4
2002 3
2003 2
2004 3
2005 1
2006 3
2007 6
2008 3
2009 3
2010 1
2011 4
2012 8
2013 8
2014 8
2015 4
2016 6
2017 4
2018 4
2019 2
2020 5
2021 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

109 results
Results by year
Filters applied: . Clear all
Page 1
TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.
Petrova PS, Viller NN, Wong M, Pang X, Lin GH, Dodge K, Chai V, Chen H, Lee V, House V, Vigo NT, Jin D, Mutukura T, Charbonneau M, Truong T, Viau S, Johnson LD, Linderoth E, Sievers EL, Maleki Vareki S, Figueredo R, Pampillo M, Koropatnick J, Trudel S, Mbong N, Jin L, Wang JC, Uger RA. Petrova PS, et al. Among authors: koropatnick j. Clin Cancer Res. 2017 Feb 15;23(4):1068-1079. doi: 10.1158/1078-0432.CCR-16-1700. Epub 2016 Nov 17. Clin Cancer Res. 2017. PMID: 27856600 Free article.
Toxicology of antisense therapeutics.
Jason TL, Koropatnick J, Berg RW. Jason TL, et al. Among authors: koropatnick j. Toxicol Appl Pharmacol. 2004 Nov 15;201(1):66-83. doi: 10.1016/j.taap.2004.04.017. Toxicol Appl Pharmacol. 2004. PMID: 15519609 Review.
Role of metallothionein in carcinogenesis.
Cherian MG, Howell SB, Imura N, Klaassen CD, Koropatnick J, Lazo JS, Waalkes MP. Cherian MG, et al. Among authors: koropatnick j. Toxicol Appl Pharmacol. 1994 May;126(1):1-5. doi: 10.1006/taap.1994.1083. Toxicol Appl Pharmacol. 1994. PMID: 8184419 Review.
Intravenous ascorbic acid as an adjuvant to interleukin-2 immunotherapy.
Wagner SC, Markosian B, Ajili N, Dolan BR, Kim AJ, Alexandrescu DT, Dasanu CA, Minev B, Koropatnick J, Marincola FM, Riordan NH. Wagner SC, et al. Among authors: koropatnick j. J Transl Med. 2014 May 13;12:127. doi: 10.1186/1479-5876-12-127. J Transl Med. 2014. PMID: 24884532 Free PMC article. Review.
Antisense treatment in human prostate cancer and melanoma.
Di Cresce C, Koropatnick J. Di Cresce C, et al. Among authors: koropatnick j. Curr Cancer Drug Targets. 2010 Sep;10(6):555-65. doi: 10.2174/156800910791859452. Curr Cancer Drug Targets. 2010. PMID: 20482488 Review.
Signaling events for metallothionein induction.
Haq F, Mahoney M, Koropatnick J. Haq F, et al. Among authors: koropatnick j. Mutat Res. 2003 Dec 10;533(1-2):211-26. doi: 10.1016/j.mrfmmm.2003.07.014. Mutat Res. 2003. PMID: 14643422 Review.
TdIF1: a putative oncogene in NSCLC tumor progression.
Zhang Y, Wang Z, Huang Y, Ying M, Wang Y, Xiong J, Liu Q, Cao F, Joshi R, Liu Y, Xu D, Zhang M, Yuan K, Zhou N, Koropatnick J, Min W. Zhang Y, et al. Among authors: koropatnick j. Signal Transduct Target Ther. 2018 Oct 19;3:28. doi: 10.1038/s41392-018-0030-9. eCollection 2018. Signal Transduct Target Ther. 2018. PMID: 30345081 Free PMC article.
CD5 blockade enhances ex vivo CD8+ T cell activation and tumour cell cytotoxicity.
Alotaibi F, Rytelewski M, Figueredo R, Zareardalan R, Zhang M, Ferguson PJ, Maleki Vareki S, Najajreh Y, El-Hajjar M, Zheng X, Min WP, Koropatnick J. Alotaibi F, et al. Among authors: koropatnick j. Eur J Immunol. 2020 May;50(5):695-704. doi: 10.1002/eji.201948309. Epub 2020 Feb 25. Eur J Immunol. 2020. PMID: 31943150 Free article.
109 results